Solanezumab may slow disease progression in Alzheimer’s

Written by Alice Weatherston

Amidst intense expectation and excitement the results of the Phase III delayed–start trial of the Eli Lilly drug, termed solanezumab, has today indicated efficacy in the slowing of the progression of Alzheimer’s disease. Within the study, presented today at the Alzheimer’s Association International Conference (MD, USA; 18–23 July 2015), patients were randomly assigned into two groups either receiving active treatment from the outset, or receiving a placebo for a set period of time before commencing treatment with the active drug. 1322 people enrolled in the completed, 18-month EXPEDITION and EXPEDITION2 placebo-controlled trials, and a two-year extension trial known as EXPEDITION-EXT...

To view this content, please register now for access

It's completely free